Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 462 | 42 | 415 |
| Samples | 122 | 18 | 102 |
| Peptides | 103 | 13 | 90 |
Function
C4BPB · Complement component 4 binding protein beta
This gene encodes a member of a superfamily of proteins composed predominantly of tandemly arrayed short consensus repeats of approximately 60 amino acids. A single, unique beta-chain encoded by this gene assembles with seven identical alpha-chains into the predominant isoform of C4b-binding protein, a multimeric protein that controls activation of the complement cascade through the classical pathway. C4b-binding protein has a regulatory role in the coagulation system also, mediated through the beta-chain binding of protein S, a vitamin K-dependent protein that serves as a cofactor of activated protein C. The genes encoding both alpha and beta chains are located adjacent to each other on human chromosome 1 in the regulator of complement activation gene cluster. Alternative splicing gives rise to multiple transcript variants. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 94 amino-acid changes on canonical ENST00000367078 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in C4BPB · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in C4BPB – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Endometrial Carcinoma | 0/42 0% | 10/612 2% |
| Hodgkins Lymphoma | 1/16 6% | 1/122 1% |
| Melanoma | 2/210 1% | 28/1899 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Other Sarcomas | 2/69 3% | 3/699 0% |
| Non-Cancerous | 0/104 0% | 6/830 1% |
| Other Solid Cancers | 2/94 2% | 8/1515 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 4/810 0% |
| Bladder Carcinoma | 0/58 0% | 4/956 0% |
| Colorectal Carcinoma | 2/143 1% | 7/3239 0% |
| Ovarian Carcinoma | 2/109 2% | 1/998 0% |
| Glioma | 0/52 0% | 5/2127 0% |
| Gastric Carcinoma | 0/74 0% | 4/1809 0% |
| Hepatocellular Carcinoma | 0/46 0% | 4/2210 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 4/2550 0% |
| Neuroendocrine Tumour | 1/154 1% | 0/577 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 1/752 0% |
| Non-Small Cell Lung Carcinoma | 0/304 0% | 2/1390 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 2/1592 0% |
| Kidney Carcinoma | 0/85 0% | 2/1862 0% |
| Biliary Tract Carcinoma | 1/54 2% | 0/950 0% |
| Breast Carcinoma | 0/144 0% | 3/3264 0% |
| B-Lymphoblastic Leukemia | 2/55 4% | 0/2640 0% |
| Head and Neck Carcinoma | 0/85 0% | 1/1574 0% |
| Prostate Carcinoma | 0/13 0% | 1/2105 0% |
| Other Blood Cancers | 0/61 0% | 1/2725 0% |
Mutation Distribution
Where C4BPB is mutated · all tissues, split by cell line vs tissue
How many mutations in C4BPB were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 52 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 462 mutations in C4BPB
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|